Skip to search formSkip to main contentSkip to account menu

rocilinostat

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Histone deacetylase 6 inhibitor ACY1215 ameliorates mitochondrial dynamic and function injury in hepatocytes by activating AMPK signaling pathway in acute liver failure mice.
Acute liver failure (ALF) is often accompanied by dynamic and functional disorders of mitochondria in hepatocytes. The histone… 
2019
2019
Structural and energetic basis for the inhibitory selectivity of both catalytic domains of dimeric HDAC6
Abstract HDAC6 is a protein involved in cancer, neurodegenerative disease and inflammatory disorders. To date, the full three… 
2017
2017
Searching the conformational complexity and binding properties of HDAC6 through docking and molecular dynamic simulations
Histone deacetylases (HDACs) are a family of proteins involved in the deacetylation of histones and other non-histones substrates… 
2017
2017
Validation of an LC-MS/MS method for simultaneous detection of four HDAC inhibitors - belinostat, panobinostat, rocilinostat and vorinostat in mouse plasma and its application to a mouse…
A sensitive and rapid LC-MS/MS method was developed and validated for the simultaneous quantitation of four HDAC inhibitors… 
2017
2017
[Protective effect of the histone deacetylase inhibitor ACY1215 against brain edema in mice with acute liver failure].
Objective: To investigate the protective effect of ACY1215 (Rocilinostat), a histone deacetylase inhibitor, against brain edema… 
2016
2016
Sensitive method for the determination of rocilinostat in small volume mouse plasma by LC-MS/MS and its application to a pharmacokinetic study in mice.
A highly sensitive, specific and rapid LC-ESI-MS/MS method has been developed and validated for the quantification of… 
2016
2016
Rational design and diversity-oriented synthesis of peptoid-based selective HDAC 6 inhibitors †
Histone deacetylases (HDACs) catalyze the cleavage of acetyl groups from N-acetyl-lysine residues of histones and non-histone… 
Review
2014
Review
2014
Current strategies for treatment of relapsed/refractory multiple myeloma
In spite of significant advances in the management of multiple myeloma (MM), the disease remains incurable and nearly all… 
2014
2014
Preclinical Screening of the HDAC6 Inhibitor Rocilinostat (ACY-1215) Combined with Bendamustine in Lymphoma Cell Lines
Background and Purpose. Histone deacetylase (HDAC) inhibitors are emerging as an exciting new therapeutic option for lymphoid… 
2012
2012
Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study
Abstract 4061 Introduction The rate of relapse in multiple myeloma (MM) remains high despite novel therapies such as the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)